Skip to main content

Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands

Author(s): Remillard, David; Buckley, Dennis L; Paulk, Joshiawa; Brien, Gerard L; Sonnett, Matthew; et al

To refer to this page use:
Abstract: The bromodomain-containing protein BRD9, a subunit of the human BAF (SWI/SNF) nucleosome remodeling complex, has emerged as an attractive therapeutic target in cancer. Despite the development of chemical probes targeting the BRD9 bromodomain, there is a limited understanding of BRD9 function beyond acetyl-lysine recognition. We have therefore created the first BRD9-directed chemical degraders, through iterative design and testing of heterobifunctional ligands that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex. Degraders of BRD9 exhibit markedly enhanced potency compared to parental ligands (10- to 100-fold). Parallel study of degraders with divergent BRD9-binding chemotypes in models of acute myeloid leukemia resolves bromodomain polypharmacology in this emerging drug class. Together, these findings reveal the tractability of non-BET bromodomain containing proteins to chemical degradation, and highlight lead compound dBRD9 as a tool for the study of BRD9.
Publication Date: 15-May-2017
Citation: Remillard, David, Buckley, Dennis L, Paulk, Joshiawa, Brien, Gerard L, Sonnett, Matthew, Seo, Hyuk-Soo, Dastjerdi, Shiva, Wühr, Martin, Dhe-Paganon, Sirano, Armstrong, Scott A, Bradner, James E. (2017). Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.. Angewandte Chemie (International ed. in English), 56 (21), 5738 - 5743. doi:10.1002/anie.201611281
DOI: doi:10.1002/anie.201611281
ISSN: 1433-7851
EISSN: 1521-3773
Pages: 5738 - 5743
Language: eng
Type of Material: Journal Article
Journal/Proceeding Title: Angewandte Chemie (International ed. in English)
Version: Author's manuscript

Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.